Cargando…

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients

OBJECTIVE: We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. METHODS: A systematic search of publications about randomized controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, Hang, Zeng, Xuehui, Zhang, Chunlei, Song, Linli, Xu, Jiarui, Hou, Zhihui, Xie, Siya, Tao, Zheng, He, Jincai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052784/
https://www.ncbi.nlm.nih.gov/pubmed/33865413
http://dx.doi.org/10.1186/s13019-021-01452-8
_version_ 1783679993414418432
author Ouyang, Hang
Zeng, Xuehui
Zhang, Chunlei
Song, Linli
Xu, Jiarui
Hou, Zhihui
Xie, Siya
Tao, Zheng
He, Jincai
author_facet Ouyang, Hang
Zeng, Xuehui
Zhang, Chunlei
Song, Linli
Xu, Jiarui
Hou, Zhihui
Xie, Siya
Tao, Zheng
He, Jincai
author_sort Ouyang, Hang
collection PubMed
description OBJECTIVE: We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. METHODS: A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality. RESULTS: EES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) (p = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52–0.99, p = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26–0.73, p = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28–0.98, p = 0.04) and PES (RR = 0.18, 95% CI: 0.07–0.51, p = 0.001). CONCLUSION: Among those three types of stents, EES should be the first recommended stent for DM patients.
format Online
Article
Text
id pubmed-8052784
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80527842021-04-19 A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients Ouyang, Hang Zeng, Xuehui Zhang, Chunlei Song, Linli Xu, Jiarui Hou, Zhihui Xie, Siya Tao, Zheng He, Jincai J Cardiothorac Surg Research Article OBJECTIVE: We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. METHODS: A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality. RESULTS: EES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) (p = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52–0.99, p = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26–0.73, p = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28–0.98, p = 0.04) and PES (RR = 0.18, 95% CI: 0.07–0.51, p = 0.001). CONCLUSION: Among those three types of stents, EES should be the first recommended stent for DM patients. BioMed Central 2021-04-17 /pmc/articles/PMC8052784/ /pubmed/33865413 http://dx.doi.org/10.1186/s13019-021-01452-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ouyang, Hang
Zeng, Xuehui
Zhang, Chunlei
Song, Linli
Xu, Jiarui
Hou, Zhihui
Xie, Siya
Tao, Zheng
He, Jincai
A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
title A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
title_full A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
title_fullStr A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
title_full_unstemmed A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
title_short A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
title_sort meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052784/
https://www.ncbi.nlm.nih.gov/pubmed/33865413
http://dx.doi.org/10.1186/s13019-021-01452-8
work_keys_str_mv AT ouyanghang ametaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT zengxuehui ametaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT zhangchunlei ametaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT songlinli ametaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT xujiarui ametaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT houzhihui ametaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT xiesiya ametaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT taozheng ametaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT hejincai ametaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT ouyanghang metaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT zengxuehui metaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT zhangchunlei metaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT songlinli metaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT xujiarui metaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT houzhihui metaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT xiesiya metaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT taozheng metaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients
AT hejincai metaanalysisofeverolimuselutingstentsversussirolimuselutingstentsandpaclitaxelelutingstentsindiabeticpatients